Bright Minds Biosciences (DRUG) Assets Average (2020 - 2026)

Bright Minds Biosciences (DRUG) has 6 years of Assets Average data on file, last reported at $146.5 million in Q1 2026.

• Quarterly Assets Average rose 260.95% year-over-year to $146.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.5 million (up 260.95% YoY) and the FY2025 annual result came in at $32.9 million, up 585.16% from the prior year.
• Assets Average improved to $146.5 million in Q1 2026, from $63.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $146.5 million in Q1 2026 to a low of $4.5 million in Q3 2024.
• A 5-year average of $25.7 million and a median of $8.1 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average plunged 52.39% — and 2025, when it jumped 994.67%.
• Tracing DRUG's Assets Average over 5 years: stood at $8.9 million in 2022, then plunged by 42.68% to $5.1 million in 2023, then surged by 354.16% to $23.1 million in 2024, then soared by 173.37% to $63.3 million in 2025, then surged by 131.56% to $146.5 million in 2026.
• The last three Assets Average figures came in at $146.5 million (Q1 2026), $63.3 million (Q4 2025), and $49.6 million (Q3 2025), per Business Quant data.